Moderna Inc. launched the much anticipated, largest-ever drug developer initial public offering raising $604.3m on Dec. 6, but the IPO landed with a thud, reflecting ongoing unease in the US stock market, which has been particularly uncomfortable for biotechnology stocks.
The Cambridge, Mass.-based developer of messenger RNA (mRNA) therapeutics and vaccines sold 26.3m shares at $23 each, but saw its stock fall 19.1% on its first day of trading to close at $18.60 on Dec
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?